Q-omics provides the consensus-scored OR6N1 profile across patient tissues and cancer cell-line models. OR6N1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR6N1 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, OR6N1 RNA expression shows 5,965 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where OR6N1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR6N1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR6N1 survival associations across molecular data types. OR6N1 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR6N1 RNA expression–survival associations across cancer types. High OR6N1 expression shows unfavorable associations in STAD, CHOL, DLBC, GBM and SKCM, but favorable associations in LAML. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for OR6N1 RNA expression.
This table summarizes OR6N1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR6N1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR6N1 shows lower tumor expression in LUAD, LUSC, KIRC and KICH. The LUAD box plot shows higher OR6N1 RNA expression in normal versus tumor tissue (log2 FC = −0.143, t-test p < 0.001).
This table shows molecular features associated with OR6N1 in patient tissues and cancer cell lines. In patient samples, OR6N1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR6N1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
